Human cluster of differentiation 73(CD73) ELISA Kit

Instructions
Code CSB-E14099h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name cluster of differentiation 73(CD73)
Alternative Names 5' NT ELISA Kit; 5' nucleotidase (CD73) ELISA Kit; 5' nucleotidase precursor ELISA Kit; 5' nucleotidase; ecto ELISA Kit; 5' nucleotidase; ecto (CD73) ELISA Kit; 5'-NT ELISA Kit; 5'-nucleotidase ELISA Kit; 5NTD_HUMAN ELISA Kit; CD73 ELISA Kit; CD73 antigen ELISA Kit; E5NT ELISA Kit; Ecto 5' nucleotidase ELISA Kit; Ecto-5'-nucleotidase ELISA Kit; eN ELISA Kit; eNT ELISA Kit; NT ELISA Kit; NT5 ELISA Kit; NT5E ELISA Kit; NTE ELISA Kit; Purine 5 Prime Nucleotidase ELISA Kit
Abbreviation CD73
Uniprot No. P21589
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 3.12 ng/mL-200 ng/mL
Sensitivity 0.78 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CD73 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %85
Range %81-91
1:2Average %99
Range %93-103
1:4Average %99
Range %95-103
1:8Average %94
Range %88-98
Recovery
The recovery of human CD73 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9692-98
EDTA plasma (n=4)9693-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
2002.498 2.482 2.490 2.363
1001.932 1.817 1.875 1.748
501.276 1.256 1.266 1.139
250.727 0.714 0.721 0.594
12.50.468 0.444 0.456 0.329
6.250.343 0.321 0.332 0.205
3.120.222 0.212 0.217 0.090
00.129 0.125 0.127  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
Gene References into Functions
  1. Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
  2. High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
  3. Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
  4. High CD73 expression is associated with breast cancer. PMID: 29047106
  5. High CD73 expression is associated with neoplasms. PMID: 29514610
  6. NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
  7. soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
  8. High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
  9. analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
  10. The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
  11. this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
  12. high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
  13. Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
  14. we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
  15. Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
  16. Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
  17. Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
  18. HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
  19. High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
  20. Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
  21. High CD73 expression is associated with cervical cancer. PMID: 28202050
  22. Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
  23. Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
  24. CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
  25. CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
  26. This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
  27. concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
  28. Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
  29. Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
  30. CD73 may play an important role in breast cancer stem cells. PMID: 27670764
  31. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
  32. Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
  33. These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
  34. CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
  35. Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
  36. The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
  37. CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
  38. report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
  39. findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
  40. CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
  41. these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
  42. This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
  43. role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
  44. Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
  45. Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
  46. rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
  47. Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
  48. The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
  49. CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
  50. It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814

Show More

Hide All

Involvement in disease Calcification of joints and arteries (CALJA)
Subcellular Location Cell membrane, Lipid-anchor, GPI-anchor
Protein Families 5'-nucleotidase family
Database Links

HGNC: 8021

OMIM: 129190

KEGG: hsa:4907

STRING: 9606.ENSP00000257770

UniGene: Hs.153952

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1